Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer
NCT03257163 is a phase 2 interventional trial sponsored by Rutgers, The State University of New Jersey. As of 21 Nov 2026, it is active and no longer recruiting. It studies Capecitabine and Pembrolizumab in Epstein-Barr Virus Positive, Gastric Adenocarcinoma and 9 more conditions. The registry lists an enrollment of 40 participants at 4 sites in 1 country. The registry lists a start date of 29 Sept 2017 and a primary completion date of 31 Aug 2026. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03257163 |
| Status | Active not recruiting |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Rutgers, The State University of New Jersey |
| Enrollment | 40 |
| Registered sites | 4 |
| Countries | 1 |
| Conditions | Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7 and 5 more conditions |
| Drugs | Capecitabine and Pembrolizumab |
| Start | 29 Sept 2017 |
| Primary completion | 31 Aug 2026 |
| Study completion | 31 Dec 2026 |
| Last update posted | 20 Jan 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Emory University
Atlanta
- Rwjbarnabas Health - Robert Wood Johnson University Hospital, Hamilton
Hamilton
- Rutgers Cancer Institute of New Jersey
New Brunswick
- Montefiore Medical Center
The Bronx
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03257163
Each answer restates registry values shown on this page.
What is NCT03257163?
NCT03257163 is a phase 2 interventional trial sponsored by Rutgers, The State University of New Jersey. It studies Capecitabine and Pembrolizumab in Epstein-Barr Virus Positive, Gastric Adenocarcinoma and 9 more conditions.
Is NCT03257163 recruiting?
As of 21 Nov 2026, it is active and no longer recruiting.
Who leads NCT03257163?
The registry names Salma Jabbour (principal investigator, Rutgers Cancer Institute of New Jersey) as the overall official.
Where does NCT03257163 run?
The registry lists 4 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03257163 study?
The registered drug and biological interventions are Capecitabine and Pembrolizumab.
When is NCT03257163 expected to complete?
The registry lists a primary completion date of 31 Aug 2026 and a study completion date of 31 Dec 2026. The sponsor last updated the record on 20 Jan 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.